hVIVO (LON:HVO) Trading Up 23% - Should You Buy?

hVIVO plc (LON:HVO - Get Free Report)'s share price was up 23% during mid-day trading on Monday . The company traded as high as GBX 11 ($0.15) and last traded at GBX 10.70 ($0.14). Approximately 24,253,932 shares traded hands during mid-day trading, an increase of 569% from the average daily volume of 3,624,890 shares. The stock had previously closed at GBX 8.70 ($0.12).

Wall Street Analyst Weigh In

Separately, Shore Capital reaffirmed a "buy" rating on shares of hVIVO in a research note on Friday, May 30th.

hVIVO Trading Up 2.3%

The firm has a market cap of £77.83 million, a PE ratio of 4.54 and a beta of 0.97. The business has a 50-day moving average price of GBX 15.82 and a two-hundred day moving average price of GBX 17.61. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16.

hVIVO (LON:HVO - Get Free Report) last announced its quarterly earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. Analysts forecast that hVIVO plc will post 1.5492958 EPS for the current year.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.